&lt;p&gt;Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel&lt;/p&gt;

Yu, Zhen; Li, Xundou; Duan, Jiaqi; Yang, Xiao

doi:10.2147/ijn.s267177

Cited by 55 publications

(22 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the average zeta-potential of BSA-Apt was −8.32 mV ( Figure 3 C). The negative charges of the BSA-Apt might prevent the nanoparticles from agglomeration and maintain the stability [ 40 ].…”

Section: Resultsmentioning

confidence: 99%

Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo

Yao

et al. 2022

Molecules

Self Cite

View full text Add to dashboard Cite

The PD-1/PD-L1 pathway blockade can generate a good clinical response by reducing immunosuppression and provoking durable antitumor immunity. In addition to antibodies, aptamers can also block the interaction between PD-1 and PD-L1. For the in vivo application, however, free aptamers are usually too small in size and quickly removed from blood via glomerular filtration. To avoid renal clearance of aptamer, we conjugated the PD-L1 aptamer to albumin to form a larger complex (BSA-Apt) and evaluated whether BSA-Apt would enhance the in vivo antitumor efficacy. The PD-L1 aptamer was thiol-modified and conjugated to the amino group of BSA via a SMCC linker. The average size of BSA-Apt was 11.65 nm, which was above the threshold for renal clearance. Functionally, BSA-Apt retained the capability of the PD-L1 aptamer to bind with PDL1-expressing tumor cells. Moreover, both the free aptamer and BSA-Apt augmented the PBMC-induced antitumor cytotoxicity in vitro. Furthermore, BSA-Apt generated a significantly stronger antitumor efficacy than the free PD-L1 aptamer in vivo without raising systemic toxicity. The results indicate that conjugating the PD-L1 aptamer to albumin may serve as a promising strategy to improve the in vivo functionality of the aptamer and that BSA-Apt may have application potential in cancer immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo

Yao

et al. 2022

Molecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…AS1411 has been linked to various types of nanoparticles due to its selective binding to nucleolin, a protein overexpressed on the cell surface and inside cancer cells [45][46][47][48][49]. Notably, a marked improvement of cytotoxicity has been previously obtained by increasing the loading (more than 100 molecules) of AS1411 on the surface of gold nanostars [50].…”

Section: Discussionmentioning

confidence: 99%

AS1411 Aptamer Linked to DNA Nanostructures Diverts Its Traffic Inside Cancer Cells and Improves Its Therapeutic Efficacy

et al. 2021

View full text Add to dashboard Cite

The nucleolin-binding G-quadruplex AS1411 aptamer has been widely used for cancer therapy and diagnosis and linked to nanoparticles for its selective targeting activity. We applied a computational and experimental integrated approach to study the effect of engineering AS1411 aptamer on an octahedral truncated DNA nanocage to obtain a nanostructure able to combine selective cancer-targeting and anti-tumor activity. The nanocages functionalized with one aptamer molecule (Apt-NC) displayed high stability in serum, were rapidly and selectively internalized in cancer cells through an AS1411-dependent mechanism, and showed over 200-fold increase in anti-cancer activity when compared with the free aptamer. Comparison of Apt-NCs and free AS1411 intracellular distribution showed that they traffic differently inside cells: Apt-NCs distributed through the endo-lysosomal pathway and were never found in the nuclei, while the free AS1411 was mostly found in the perinuclear region and in nucleoli. Molecular dynamics simulations indicated that the aptamer, when linked to the nanocage, sampled a limited conformational space, more confined than in the free state, which is characterized by a large number of metastable conformations. A different intracellular trafficking of Apt-NCs compared with free aptamer and the confined aptamer conformations induced by the nanocage were likely correlated with the high cytotoxic enhancement, suggesting a structure–function relationship for the AS1411 aptamer activity.

show abstract

“…Albumin represents an appealing protein-based macromolecular carrier due to its non-toxicity, non-immunogenicity, biocompatibility, easy incorporation of various drugs, and ability to bind with proteins [21,82,83]. Albumin nanoparticles have been shown to exhibit enhanced affinity for anti-cancer drugs, including paclitaxel [84][85][86][87] (FDAapproved nanoformulation as Abraxane ® /ABI-007 (Celgene) [88]), doxorubicin [87,[89][90][91][92], docetaxel [93][94][95][96], tacrolimus [87,97], and curcumin [98,99].…”

Section: Albuminmentioning

confidence: 99%

Polymer-Based Nanosystems—A Versatile Delivery Approach

Niculescu

Grumezescu

2021

Materials

View full text Add to dashboard Cite

Polymer-based nanoparticles of tailored size, morphology, and surface properties have attracted increasing attention as carriers for drugs, biomolecules, and genes. By protecting the payload from degradation and maintaining sustained and controlled release of the drug, polymeric nanoparticles can reduce drug clearance, increase their cargo’s stability and solubility, prolong its half-life, and ensure optimal concentration at the target site. The inherent immunomodulatory properties of specific polymer nanoparticles, coupled with their drug encapsulation ability, have raised particular interest in vaccine delivery. This paper aims to review current and emerging drug delivery applications of both branched and linear, natural, and synthetic polymer nanostructures, focusing on their role in vaccine development.

show abstract

<p>Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel</p>

Cited by 55 publications

References 57 publications

Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo

Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo

AS1411 Aptamer Linked to DNA Nanostructures Diverts Its Traffic Inside Cancer Cells and Improves Its Therapeutic Efficacy

Polymer-Based Nanosystems—A Versatile Delivery Approach

Contact Info

Product

Resources

About